Estrogen Dominance Symptoms: The Three-Step Clearance Pathway, Graded on Human Evidence

"Estrogen dominance" is one of the most searched and least precisely defined phrases in women's health. This guide does what the pages ranking above it do not: it walks the full estrogen clearance pathway as one connected system, then grades every popular intervention on the actual human evidence, including a trial that went against the supplement it was testing.

What Estrogen Dominance Actually Means

In plain English, estrogen dominance describes a relative imbalance between estrogen and progesterone, not necessarily a high estrogen level on a lab report. Two very different situations get folded into the same label:

1. Estrogen is genuinely high. This happens with certain medical conditions, some medications, and significant excess body fat, since fat tissue makes estrogen.
2. Estrogen is normal but progesterone is low. This is the far more common pattern in the years leading into menopause.

Both patterns produce a similar symptom list, and they need different conversations with a clinician.

The ovaries are the headline source of estrogen, not the only one. Fat tissue converts androgens into estrogen through an enzyme called aromatase. After estrogen does its job, it has to be broken down and carried out of the body, which is where the liver and the gut take over. That last part is the piece nearly every article skips, and it is why a supplement can change how estrogen is processed without changing how much of it exists.

Why the Term Is Useful Even Without a Formal Diagnosis

Here is the honest part, and it is the part the internet usually avoids. "Estrogen dominance" is a functional-medicine term, not a formal standalone clinical diagnosis. What the U.S. Department of Veterans Affairs Whole Health Library does say outright is that lab testing is "likely unnecessary for most women."

Should the term be thrown out? No, for three reasons.

• It captures a real pattern. Estrogen and progesterone genuinely move in different directions during perimenopause, because progesterone falls earlier and faster.
• It gives patients language for symptoms that might otherwise be dismissed one at a time.
• It points at modifiable levers. Body fat, alcohol, fiber, gut health, and environmental exposures all touch the pathway.

What the term is not

• Not a diagnosis from a blood test alone, and not a disease. No supplement treats it.
• Not a synonym for "high estrogen." Many people using the phrase have estrogen in the normal range.
• Not a reason to skip a real workup. Thyroid problems, anemia, and sleep disorders overlap heavily with this symptom list.

Use the term as a starting point for a conversation, never as a conclusion. Agape's role is to support the nutritional side of a clinician's plan, not to replace it.

Signs People Describe as High Estrogen

Symptoms overlap heavily with perimenopause, PMS, thyroid issues, and plain sleep debt, which is exactly why self-diagnosis from a symptom list is unreliable. Still, these are the patterns most commonly reported:

• Breast tenderness or lumpy breast tissue, often cyclical.
• Cycle changes: heavier bleeding, shorter cycles, or new irregularity.
• Bloating and water retention, especially in the week before a period.
• Mood shifts: irritability, anxiety, or tearfulness that tracks the cycle.
• Midsection weight gain that does not respond to normal effort.
• Headaches, particularly cyclical ones.
• Sleep disruption, night waking, low libido, and brain fog before bleeding starts.

Notice how many of these also describe a normal perimenopausal transition. That is not a flaw in the list. It is the reason the label is a hypothesis, not a verdict.

The Three-Step Estrogen Clearance Pathway

This is the centerpiece, and it is the section no competing article assembles. Estrogen does not simply appear and disappear. It moves through three stages, and a bottleneck at any one of them changes how much active estrogen stays in circulation. Read them as one conveyor belt, not three separate topics.

Step 1: Production and the Aromatase Enzyme

Aromatase converts androgens into estrogens. It lives in the ovaries, but also in fat tissue, the brain, and the adrenal glands.

More aromatase activity in fat tissue means more estrogen is produced locally in that tissue. A 2025 study in the Journal of Clinical Endocrinology and Metabolism (PMID 39833659) found aromatase expression was higher in the subcutaneous fat of men with obesity, correlating with adiposity, high blood glucose, and insulin resistance. That is a measured human association, not proof that weight loss shifts estrogen metabolites. Our weight and metabolism guide covers the metabolic side of this step.

Step 2: The Liver, Phase I and Phase II

Once estrogen has done its job, it travels to the liver to be prepared for removal, in two phases that do different jobs.

• Phase I uses cytochrome P450 (CYP) enzymes to add a hydroxyl group. This is where the 2-hydroxy and 16-alpha-hydroxy metabolites are created. Phase I makes estrogen more reactive, not less.
• Phase II conjugates the result, attaching glucuronic acid, sulfate, or a methyl group. Conjugation is what actually deactivates estrogen and tags it for excretion.

Phase I without adequate Phase II is a half-finished job. Conjugated estrogen then leaves the liver in bile, so sluggish bile flow slows that exit route down. Our detox and methylation guide covers the liver-phase nutrients in detail.

Step 3: The Gut, the Estrobolome, and Beta-Glucuronidase

The estrobolome is the collection of gut bacteria whose enzymes can metabolize estrogens. A 2017 review in Maturitas (PMID 28778332) sets out the estrogen-gut microbiome axis and the role of beta-glucuronidase in regulating circulating estrogen.

The key enzyme is beta-glucuronidase. During Phase II the liver attaches glucuronic acid to estrogen to deactivate it. Beta-glucuronidase, produced by gut bacteria, removes that glucuronic acid again, returning estrogen to an active form that can be reabsorbed rather than excreted. A 2019 paper in the Journal of Biological Chemistry (PMID 31636122) describes this directly.

In plain terms: high beta-glucuronidase activity means estrogen gets recycled instead of leaving. Our digestion and gut health guide covers the gut side of this step.

Supporting work includes a 2012 cross-sectional study in the Journal of Translational Medicine (PMID 23259758) on fecal microbial determinants of estrogens, and a 2021 review in Gut Microbes (PMID 33722164). Label this honestly: mechanism and association, not intervention data.

Why the Steps Only Work as One System

Fixing only Phase I while the gut recycles aggressively is like mopping a floor with the tap still running. Fixing only the gut while Phase II lacks its nutrients leaves the job half done upstream. And ignoring aromatase means never addressing where the extra production comes from.

A single ingredient cannot fix a three-step pathway. That is the central practical point of this article, and it is why the supplement aisle, which sells single ingredients, keeps disappointing people.

The 2-Hydroxy vs 16-Alpha-Hydroxy Split

Phase I does not produce one metabolite. It produces several, and two get most of the attention.

• 2-hydroxyestrone (2-OHE1) comes from the C-2 pathway and is generally described as the more weakly estrogenic of the two.
• 16-alpha-hydroxyestrone (16-alpha-OHE1) comes from the C-16 pathway and is described as more estrogenic in its activity.

Because of that difference, a lot of content calls C-2 "good" and C-16 "bad," and treats the 2-OHE1 to 16-alpha-OHE1 ratio as a score to improve.

Hold that framing loosely. Both metabolites are normal products of estrogen metabolism. Neither is a toxin, and a ratio that shifts is not the same thing as a health outcome improving. Its genuine use is as a research marker for whether an intervention changes how the liver handles estrogen, which is how the trials below use it.

Is the Urine Metabolite Ratio Test Reliable

Short answer: treat it as contested, not as a definitive test.

• Urine captures what was excreted, not what is circulating. A low ratio could reflect fast clearance rather than high production.
• Hydration, timing, and recent meals shift the numbers, and reference ranges are not standardized across commercial labs.
• A ratio is not a diagnosis. The VA's own position is that lab testing is often unnecessary for most women.

If a test result is being used to sell you a protocol, that is a warning sign. A clinician may still order metabolite testing for a specific reason inside a broader workup, which is reasonable.

Every Intervention Graded on the Human Evidence

This is the part that exists nowhere else in the current search results. Every popular recommendation gets an explicit grade.

How to read the grades: Strong human data means multiple human studies measuring the marker directly. Mixed or negative means human studies exist, but results conflict or a trial failed. Mechanism only means the rationale is real and the human trials are not there.

• I3C (indole-3-carbinol): Strong human data, from small trials. The only item here with a supportive human trial record.
• DIM (diindolylmethane): Mixed or negative. A randomized trial at 75 mg/day for 30 days did not significantly shift the metabolite ratio.
• Calcium-D-glucarate: Mechanism only. No human clinical trial was found.
• Chasteberry (Vitex agnus-castus): Mixed or negative. Small trials, mostly for cyclical breast pain and PMS, not estrogen endpoints. A 2003 review in Phytomedicine (PMID 12809367) covers its pharmacology, and the most recent human evidence is a 2026 case series of 6 adolescents aged 12 to 17 (PMID 42424191). A case series is not a trial.
• Fiber: Mixed or negative. A controlled feeding arm did not move the ratio, and a cross-sectional study found no correlation with serum estradiol or estrone.
• Cruciferous vegetables: Mechanism only. They supply I3C precursors, but no trial in this evidence base fed people broccoli and measured estrogen handling.
• Probiotics: Mechanism only. Beta-glucuronidase is a bacterial product, so the target is legitimate, but the human gut-estrogen studies are observational. Our guide on how to choose a probiotic covers gut support on better evidence.
• Weight and fat loss: Mechanism only. Fat tissue expresses aromatase, so body composition is plausible, but no trial shows fat loss shifts the metabolite ratio. The DIM trial below found body fat fell significantly while the ratio did not move.
• Alcohol reduction: Mechanism only. A 2024 study found ethanol increased aromatase mRNA in human fat cells, but no acute effect appeared in rats in vivo (PMID 38873224).
• Endocrine-disruptor avoidance: Mechanism only. The Endocrine Society's two scientific statements (PMID 19502515, PMID 26544531) and a review in its journal Endocrine Reviews on low-dose, nonmonotonic dose responses (PMID 22419778) establish the biology, but no trial has measured whether personal avoidance changes metabolite ratios.

The honest headline: only one item on this list earns a strong grade, and its trials were small.

DIM and I3C: The Real Trial Record

DIM is the most aggressively marketed supplement in this space. Its trial record is genuinely mixed, and the negative trial never makes it onto a product page.

I3C is the parent compound, and DIM is what it becomes in the stomach, which makes the older I3C research the closest thing to a human evidence base here.

Michnovicz and Bradlow, in the Journal of the National Cancer Institute in 1990 (PMID 2342128), gave 500 mg of I3C daily for one week and found estradiol 2-hydroxylation rose from 29.3 percent to 45.6 percent (P < .001). Read the limits: 500 mg, one week, a small study. It is a real human finding, not a long-term outcome study.

The follow-up work is broader. Michnovicz, Adlercreutz, and Bradlow, in the same journal in 1997 (PMID 9168187), used 6 to 7 mg per kg per day in 7 men for one week and 10 women for two months. I3C significantly increased urinary C-2 estrogens and lowered estradiol, estrone, estriol, and 16-alpha-hydroxyestrone.

Then came the trial that makes this category honest. Bradlow and colleagues, in Cancer Epidemiology, Biomarkers and Prevention in 1994 (PMID 7827590), ran a randomized trial with three arms of 20 subjects each, for three months:

• 400 mg per day of I3C raised the 2-hydroxyestrone to estriol ratio at month one and held it through month three.
• 20 grams per day of added alpha-cellulose fiber did not change the ratio at all.
• 3 of the 20 women were non-responders, which the authors attributed to individual resistance.

That single trial separates a nutrient with a measurable effect from a popular one with no effect on the same marker. It is also the source of this article's most important caveat: individual response varies. A smaller 1998 study in the International Journal of Obesity (PMID 9539190) gave 5 obese premenopausal women 400 mg of I3C for two months and found increased 2-hydroxylation. Five people. A hint, not a result.

The DIM trial that did not work

Godinez-Martinez and colleagues, in Nutrition and Cancer in 2023 (PMID 36111381), ran a randomized, double-blind trial in 60 premenopausal women using 75 mg per day of DIM, delivered as 300 mg of a DIM-BR complex, for 30 days.

The estradiol metabolite ratio did not increase significantly (p > 0.05), with only a non-significant trend 30 days after stopping (p = 0.06). One thing did change: body fat percentage fell significantly versus placebo (p = 0.04). The authors concluded the dose was "ineffective in increasing EMUR" and called for more research into dose and duration.

DIM is not proven. At 75 mg per day for 30 days, the marker that matters most did not move.

The large DIM study that is not a trial

Newman and Smeaton, in BMC Complementary Medicine and Therapies in 2024 (PMID 39578798), ran a retrospective cohort study comparing 909 women reporting DIM use against 18,385 who did not. They found significant differences in almost every urinary estrogen metabolite measured, except 2-methoxyestrone. This is observational data. Women who choose DIM differ from those who do not in ways no adjustment fully captures.

Verdict: promising, with a mixed record and one clean negative at a common dose. Our guide on DIM and estrogen metabolism goes deeper on the mechanism and the drug interactions to check first.

Calcium-D-Glucarate Has No Human Trial

Calcium-D-glucarate is sold on the promise that it inhibits beta-glucuronidase, which would reduce estrogen recycling in the gut. The mechanism makes sense. That is the whole case.

Here is the plain statement: no human clinical trial has tested calcium-D-glucarate on its own for estrogen metabolism.

What exists is a 2002 narrative review in Alternative Medicine Review (PMID 12197785) stating that it inhibits beta-glucuronidase and that its "potential clinical applications include regulation of estrogen metabolism," an animal study in mouse skin (PMID 17725531), and an in-vitro study on human platelets (PMID 20873960).

That is mechanism, animal, and in-vitro work. It is not clinical evidence. Every other page in this niche presents calcium-D-glucarate as established. It is not established.

Why Fiber Is Not the Estrogen Solution the Internet Promises

"Eat more fiber to clear estrogen" appears on nearly every page ranking for these keywords. The human data is weak, and one controlled trial went the other way.

In the 1994 randomized trial described above (PMID 7827590), the arm given 20 grams per day of added alpha-cellulose fiber showed no change in the estrogen metabolite ratio. Twenty grams is a real dose, and it did nothing to the marker.

Then look at the observational data. A 2021 cross-sectional study in Nutrition and Cancer (PMID 32590914) measured serum estradiol and estrone against dietary fiber intake and specific bacterial species in 29 postmenopausal women from a single clinical cohort. Serum estradiol and estrone were not correlated with fiber, and were not correlated with the bacteria examined either. The only signal was a non-significant trend for soluble fiber against estradiol (r = -0.30, p = 0.12).

So fiber's effect on circulating estrogen is unproven, and its effect on the metabolite ratio was tested and came back flat.

Does that mean fiber does not matter? No. It supports bowel regularity, feeds beneficial bacteria, and regularity matters here because conjugated estrogen leaves through the gut. The correct claim is narrow: fiber supports the elimination step. It is not a proven way to lower circulating estrogen.

Can Men Have Estrogen Dominance

Men are almost entirely absent from the content ranking for this keyword, and they should not be. Men make estrogen too, and production is tied directly to body fat.

The key finding is the 2025 Journal of Clinical Endocrinology and Metabolism study (PMID 39833659): aromatase expression was higher in subcutaneous adipose tissue from men with obesity, correlating positively with adiposity, hyperglycemia, and insulin resistance. That gives men a concrete, measurable mechanism:

• More fat tissue means more aromatase, and aromatase converts androgens into estrogens.
• The association tracks metabolic health, not just weight, so blood sugar and insulin matter alongside body composition.
• The symptom pattern people describe, including chest tissue changes, reduced libido, fatigue, and mood shifts, overlaps heavily with low testosterone and thyroid issues.

Any man with these symptoms should see a clinician, not buy a supplement. The levers that make sense are unglamorous: body composition, blood sugar control, alcohol moderation, and sleep. All of them act upstream of the step where the extra estrogen is being made.

Estrogen Dominance by Life Stage

Symptom lists are drawn mostly from one life stage, and applying them to all of them causes real confusion. The same pathway behaves differently depending on where a woman is in her reproductive life.

Cycling Years

Estrogen and progesterone rise and fall on a predictable schedule. The most common pattern here is cyclical: breast tenderness, bloating, and mood shifts that arrive and depart with the cycle. Cycle-tracking is genuinely useful, because pattern beats any single day's feeling. See a clinician if cycles become heavy, painful, or irregular. Our guide to PMS supplements graded on human evidence covers this stage's nutrient questions.

Perimenopause

This is where the term fits best and where it is most often misused. Progesterone declines earlier and faster than estrogen does, so the ratio widens without estrogen necessarily being high. That means cycle-tracking becomes a poor guide, and a normal estrogen lab result does not rule the pattern out, because the issue is the ratio and the fluctuation. Focus on sleep, stress load, alcohol, body composition, and a clinician conversation about options. Our menopause hormone balance supplement guide covers the supplement questions directly.

Postmenopause

Ovarian estrogen production falls sharply, and fat tissue becomes a proportionally larger source of estrogen through aromatase, so body composition shifts from background factor to primary one. Two honest notes: the "estrogen dominance" label fits poorly here in its usual sense, because both hormones are low, and the 2021 fiber study was conducted in postmenopausal women (PMID 32590914), finding no correlation between fiber and serum estradiol or estrone. Focus here on bone, muscle, metabolic health, and gut regularity.

Safety, Interactions, and Who Should Not Self-Treat

The supplements in this category are not inert, and the interactions are real.

Chasteberry and hormonal contraception

Chasteberry's safety data do not include any reported drug interactions, but it has dopamine-related activity that can suppress prolactin, and prolactin is part of the signaling hormonal contraception depends on. Because that interaction is theoretical rather than documented, the sensible move is to talk to your prescriber before adding it if you use pills, an implant, a patch, or a hormonal IUD.

The wider safety record is reasonably reassuring. A systematic review of adverse events in Drug Safety in 2005 (PMID 15783241) found the profile tolerable, with mostly mild gastrointestinal upset, headache, and cycle changes. Tolerable is not the same as compatible with your other medications.

I3C and DIM are CYP-mediated

This interaction matters most and gets mentioned least. I3C and DIM act on cytochrome P450 enzymes, the same family the liver uses to metabolize a long list of prescription drugs, so they can plausibly change how quickly other drugs clear from your body. The concern most often raised is tamoxifen, itself metabolized through CYP enzymes. Anyone taking a medication in that category should not add an indole compound without their prescriber's explicit sign-off.

The general rule: if you take any prescription medication regularly, run new supplements past a pharmacist or prescriber first. A pharmacist is often the fastest person to ask and is trained for exactly this question.

Who should not self-treat

• You take prescription medication, particularly anything CYP-metabolized.
• You use hormonal contraception and are considering chasteberry.
• You are pregnant, breastfeeding, or trying to conceive.
• You have a diagnosed hormone-sensitive condition. That is clinician-led from start to finish.
• Your symptoms are disruptive. Persistent pelvic pain, unusual bleeding, a new breast lump, or unexplained weight change needs a clinician, promptly.

"Talk to your clinician first" is not a legal formality here. It is the actual recommendation.

A Sensible Order of Operations

If you want to act on this article, act in the order the pathway runs. It is also roughly the order of strongest to weakest evidence.

1. Get symptoms assessed by a clinician. Rule out thyroid, anemia, and sleep disorders first.
2. Work the broadest levers: sleep, alcohol moderation, body composition, and stress load.
3. Support elimination: regular bowel movements, adequate fluid, and enough fiber to stay regular. This is fiber's real job here.
4. Support bile flow, since conjugated estrogen leaves through bile. See our guide on how to improve bile flow.
5. Support liver and gut health with the nutrients phase II conjugation depends on. Our liver support supplement guide grades the options, and our guide on supplements for constipation covers the elimination side.
6. Only then consider an indole compound, knowing that I3C has the small human trials, that DIM at 75 mg for 30 days did not move the primary marker, and that roughly 1 in 7 I3C participants in the 1994 trial did not respond at all.
7. Skip calcium-D-glucarate if you want human evidence.

Notice that steps one through five are not supplements at all. That is not a sales dodge. It is what the evidence supports. For completeness, the VA library also lists I3C at 300 mg daily and EPA plus DHA at 1,000 to 2,000 mg, though no trial in this evidence base tested omega-3 against estrogen endpoints.

If you would rather not assemble this yourself, the Agape team can help you match products to the step you are actually working on, instead of stacking three ingredients that all target the same one.

What We Recommend

Two products, placed at the steps they relate to rather than stacked on the same one. There is deliberately no Step 1 card: the levers at that step are graded mechanism-only above, so nothing here carries a claim this article cannot support. The grades apply to these two as well, and neither of them treats estrogen dominance.

Protocols For Health, Methylation Minerals 30 Capsules A trace-mineral formula for Step 2, supplying the zinc, selenium, and molybdenum the liver's conjugation and antioxidant enzymes use. $21.99

Researched Nutritionals, Multi-Biome® 30 Capsules A spore-plus-live-strain probiotic, placed alongside Step 3 for the gut side of the pathway. Probiotics are graded mechanism-only, and no trial in this evidence base measured one against beta-glucuronidase or estrogen recycling. $49.98

Frequently Asked Questions

What is estrogen dominance?

A functional-medicine term for a relative imbalance between estrogen and progesterone. It is not a formal standalone clinical diagnosis, and the VA Whole Health Library notes that lab testing is "likely unnecessary for most women."

What are the signs of high estrogen?

Breast tenderness, heavier or irregular cycles, bloating and water retention, cyclical mood shifts, midsection weight gain, headaches, sleep disruption, and brain fog. All of these overlap with perimenopause, PMS, thyroid problems, and poor sleep, so a symptom list alone diagnoses nothing.

How do you lower estrogen naturally?

You do not "lower estrogen" with a supplement, and any product claiming to flush it out overstates the research. What you can influence is how estrogen is produced, conjugated, and eliminated: body composition, alcohol intake, bowel regularity, bile flow, and gut health.

Does diet help estrogen dominance?

Partly, though not in the way most articles claim. In a controlled feeding arm, 20 grams per day of added alpha-cellulose did not change the metabolite ratio. A low-fat diet shifted urinary metabolites in a six-woman study (PMID 3571427), far too small to generalize.

Is DIM worth taking for estrogen balance?

The record is mixed. In a randomized, double-blind trial of 60 premenopausal women, DIM at 75 mg per day for 30 days did not significantly increase the estrogen metabolite ratio (p > 0.05), though body fat percentage did fall (p = 0.04). A large observational study of 909 DIM users found metabolite differences, but observational data cannot establish cause. Promising, not proven.

Can men have estrogen dominance?

Men make estrogen, and aromatase in fat tissue is the main production route. A 2025 study found higher aromatase expression in the subcutaneous fat of men with obesity, correlating with adiposity, high blood glucose, and insulin resistance. Men with symptoms should see a clinician, because the symptom list overlaps with low testosterone and thyroid issues.

How do you test for estrogen dominance, and is the urine test reliable?

The urine metabolite ratio test is contested. It measures excretion rather than circulating levels, is sensitive to hydration and timing, and lacks standardized reference ranges across labs. A clinician may order it inside a broader workup. Treating a consumer-ordered ratio as a diagnosis is not.

Which supplements actually have human evidence?

On this evidence base, I3C is the only item with a supportive human trial record, and those trials were small. DIM is mixed or negative. Calcium-D-glucarate has no human clinical trial. Chasteberry has small trials for cycle symptoms, not estrogen endpoints. Fiber's effect on circulating estrogen is unproven. Probiotics, weight loss, alcohol reduction, and endocrine-disruptor avoidance are all mechanism only.

References

1. Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017;103:45-53. https://pubmed.ncbi.nlm.nih.gov/28778332/
2. Ervin SM, Li H, Lim L, et al. Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens. The Journal of biological chemistry. 2019;294(49):18586-18599. https://pubmed.ncbi.nlm.nih.gov/31636122/
3. Flores R, Shi J, Fuhrman B, et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. Journal of translational medicine. 2012;10:253. https://pubmed.ncbi.nlm.nih.gov/23259758/
4. Qi X, Yun C, Pang Y, et al. The impact of the gut microbiota on the reproductive and metabolic endocrine system. Gut microbes. 2021;13(1):1-21. https://pubmed.ncbi.nlm.nih.gov/33722164/
5. Michnovicz JJ, Bradlow HL. Induction of estradiol metabolism by dietary indole-3-carbinol in humans. Journal of the National Cancer Institute. 1990;82(11):947-949. https://pubmed.ncbi.nlm.nih.gov/2342128/
6. Michnovicz JJ, Adlercreutz H, Bradlow HL. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. Journal of the National Cancer Institute. 1997;89(10):718-723. https://pubmed.ncbi.nlm.nih.gov/9168187/
7. Bradlow HL, Michnovicz JJ, Halper M, et al. Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1994;3(7):591-595. https://pubmed.ncbi.nlm.nih.gov/7827590/
8. Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 1998;22(3):227-229. https://pubmed.ncbi.nlm.nih.gov/9539190/
9. Godínez-Martínez E, Santillán R, Sámano R, et al. Effectiveness of 3,3'-Diindolylmethane Supplements on Favoring the Benign Estrogen Metabolism Pathway and Decreasing Body Fat in Premenopausal Women. Nutrition and cancer. 2023;75(2):510-519. https://pubmed.ncbi.nlm.nih.gov/36111381/
10. Newman M, Smeaton J. Exploring the impact of 3,3'-diindolylmethane on the urinary estrogen profile of premenopausal women. BMC complementary medicine and therapies. 2024;24(1):405. https://pubmed.ncbi.nlm.nih.gov/39578798/
11. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus)--pharmacology and clinical indications. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2003;10(4):348-357. https://pubmed.ncbi.nlm.nih.gov/12809367/
12. Daniele C, Thompson Coon J, Pittler MH, et al. Vitex agnus castus: a systematic review of adverse events. Drug safety. 2005;28(4):319-332. https://pubmed.ncbi.nlm.nih.gov/15783241/
13. Erkert AK. Case Series: Real-Life Experience with Vitex Agnus-Castus Extract Ze 440 Medication in Adolescents. Complementary medicine research. 2026:1-6. https://pubmed.ncbi.nlm.nih.gov/42424191/
14. . Calcium-D-glucarate. Alternative medicine review : a journal of clinical therapeutic. 2002;7(4):336-339. https://pubmed.ncbi.nlm.nih.gov/12197785/
15. Singh J, Gupta KP. Induction of apoptosis by calcium D-glucarate in 7,12-dimethyl benz [a] anthracene-exposed mouse skin. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer. 2007;26(1):63-73. https://pubmed.ncbi.nlm.nih.gov/17725531/
16. Saluk-Juszczak J. A comparative study of antioxidative activity of calcium-D-glucarate, sodium-D-gluconate and D-glucono-1,4-lactone in a human blood platelet model. Platelets. 2010;21(8):632-640. https://pubmed.ncbi.nlm.nih.gov/20873960/
17. Ahmed F, Hetty S, Laterveer R, et al. Altered Expression of Aromatase and Estrogen Receptors in Adipose Tissue From Men With Obesity or Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. 2025;110(10):e3410-e3424. https://pubmed.ncbi.nlm.nih.gov/39833659/
18. Ardenkjær-Skinnerup J, Saar D, Christiansen S, et al. Effects of ethanol or ethylene glycol exposure on PPARγ and aromatase expression in adipose tissue. Biochemistry and biophysics reports. 2024;38:101742. https://pubmed.ncbi.nlm.nih.gov/38873224/
19. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocrine reviews. 2009;30(4):293-342. https://pubmed.ncbi.nlm.nih.gov/19502515/
20. Gore AC, Chappell VA, Fenton SE, et al. EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocrine reviews. 2015;36(6):E1-E150. https://pubmed.ncbi.nlm.nih.gov/26544531/
21. Vandenberg LN, Colborn T, Hayes TB, et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocrine reviews. 2012;33(3):378-455. https://pubmed.ncbi.nlm.nih.gov/22419778/
22. Longcope C, Gorbach S, Goldin B, et al. The effect of a low fat diet on estrogen metabolism. The Journal of clinical endocrinology and metabolism. 1987;64(6):1246-1250. https://pubmed.ncbi.nlm.nih.gov/3571427/
23. Zengul AG, Demark-Wahnefried W, Barnes S, et al. Associations between Dietary Fiber, the Fecal Microbiota and Estrogen Metabolism in Postmenopausal Women with Breast Cancer. Nutrition and cancer. 2021;73(7):1108-1117. https://pubmed.ncbi.nlm.nih.gov/32590914/

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.